CLINICAL TRIAL SUMMARY

MDACC Study No:2009-0023 (clinicaltrials.gov NCT No: NCT00941499)
Title:A phase I study of hepatic arterial infusion of oxaliplatin and/or fluorouracil in combination with systemic fluorouracil, leucovorin, bevacizumab, and/or cetuximab by KRAS mutational status and liver function for patients with advanced cancers metastatic to the liver
Principal Investigator:Apostolia M. Tsimberidou
Treatment Agent:5-Fluorouracil; Bevacizumab; Cetuximab; Leucovorin; Oxaliplatin
Study Status:Closed
Study Description:Unavailable

Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers
Phase of Study:Phase I
Treatment Agents:5-Fluorouracil
Bevacizumab
Cetuximab
Leucovorin
Oxaliplatin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Days 1 and 2 of each 21 day cycle.
Supported By:N/A
Return Visit:Baseline, Days 3-5 of each 21 day cycle.
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Apostolia M. Tsimberidou
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-792-4259
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults